AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

3,9200

30-июля-25 13:45:00

15 мин. задержка

Акции

-0,0100

-0,25%

Сегодняшний диапазон

3,9000 - 4,1000

ISIN

N/A

Источник

NASDAQ

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

22 июл 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

15 июл 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

07 июл 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

25 июн 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

16 июн 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

12 май 2025 13:01:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

05 май 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

01 май 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

09 апр 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

01 апр 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

05 мар 2025 13:01:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

26 фев 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

20 фев 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

12 фев 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

04 фев 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

13 янв 2025 04:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

19 дек 2024 05:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

02 дек 2024 05:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

12 ноя 2024 05:00:01 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

04 ноя 2024 13:36:01 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.